NCT06669117

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

A First-In-Human (FIH) Phase I/II Open-label, Multicentre, Dose Escalation and Expansion Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors Including Non-small Cell Lung Cancer (NSCLC) Harboring Mesenchymal-Epithelial Transition (MET) Alterations

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 140 (estimated)
• Sponsor: Pierre Fabre Medicament · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.

Conditions

• Solid Tumor
• MET Alteration

Interventions

Type	Name	Description
DRUG	VERT-002	Route of Administration: Intravenous

Timeline

• Start date: 2024-10-22
• Primary completion: 2030-10-21
• Completion: 2032-10-01
• First posted: 2024-11-01
• Last updated: 2025-07-02

Locations

19 sites across 9 countries: United States, Belgium, France, Germany, Italy, Netherlands, South Korea, Spain, Taiwan

Regulatory

• FDA-regulated drug study